Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
FAQ
- What is TG Therapeutics's D&A?
- TG Therapeutics (TGTX) reported D&A of $53K in Q2 2026.
- How has TG Therapeutics's D&A changed year-over-year?
- TG Therapeutics's D&A increased by 307.7% year-over-year, from $13K to $53K.
- What is the long-term trend for TG Therapeutics's D&A?
- Over 4 years (2021 to 2025), TG Therapeutics's D&A has grown at a -32.4% compound annual growth rate (CAGR), from $282K to $59K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about TG Therapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude